Osimertinib in untreated EGFR-mutated advanced NSCLC¶

One-paragraph summary¶

FLAURA randomized 556 previously untreated patients with advanced EGFR exon-19-deletion or L858R-positive NSCLC to osimertinib or standard gefitinib/erlotinib. Median PFS was 18.9 versus 10.2 months (HR 0.46), with activity across prespecified subgroups and a favorable serious-adverse-event profile; later analysis reported median OS 38.6 versus 31.8 months (Soria 2018, PMID 29151359; OS follow-up PMID 31751012).

Key findings¶

Randomized first-line comparison in classical sensitizing EGFR mutations.
Median PFS: 18.9 versus 10.2 months.
Progression/death HR: 0.46.
CNS activity made brain control part of first-line drug selection.
Later OS HR: 0.80, with median OS 38.6 versus 31.8 months (PMID 31751012).

Limitations¶

Comparator sequencing and crossover do not match every current jurisdiction.
Exon-20 insertions and many uncommon EGFR variants were not the target population.
Acquired-resistance sampling was not uniform.
The trial does not answer monotherapy versus modern intensification.

Why it matters¶

FLAURA made a third-generation, CNS-active inhibitor the first-line EGFR backbone and moved resistance planning from T790M salvage to post-osimertinib biology.

Cited by wiki pages¶

Overview
EGFR disease
Systemic therapy
Clinical trials landscape